Related Experiment Videos
Pathological synaptic plasticity in the striatum: implications for Parkinson's disease
Barbara Picconi1, Antonio Pisani, Ilaria Barone
1Clinica Neurologica, Dipartimento di Neuroscienze, Università di Roma Tor Vergata and Fondazione Santa Lucia, I.R.C.C.S., Via di Tor Vergata 135, Roma, Italy.
Neurotoxicology
|June 2, 2005
Summary
Parkinson's disease impairs striatal synaptic plasticity, but L-DOPA treatment can restore it. However, L-DOPA may impair synaptic depotentiation, potentially causing dyskinesias in Parkinson's patients.
Area of Science:
- Neuroscience
- Synaptic Plasticity
- Parkinson's Disease Pathogenesis
Background:
- Corticostriatal pathways exhibit long-term potentiation (LTP) and long-term depression (LTD).
- Synaptic depotentiation reverses LTP, essential for information processing.
- Striatal synaptic plasticity is impaired in Parkinson's disease models.
Purpose of the Study:
- To review plastic changes at striatal synapses.
- To discuss the role of synaptic plasticity in motor control.
- To explore the relevance to Parkinson's disease and L-DOPA-induced dyskinesias.
Main Methods:
- Review of existing literature on striatal synaptic plasticity.
- Analysis of findings in the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease.
- Electrophysiological recordings in L-DOPA-treated rats.
Main Results:
- L-DOPA treatment restored impaired striatal synaptic plasticity in 6-OHDA rats.
- A subset of L-DOPA-treated rats developed dyskinesias.
- Dyskinetic rats showed impaired synaptic depotentiation, but not LTP or LTD.
Conclusions:
- Impaired synaptic depotentiation may underlie L-DOPA-induced dyskinesias.
- Understanding striatal plasticity is crucial for Parkinson's disease treatment.
- Further research is needed on the mechanisms of synaptic depotentiation and L-DOPA side effects.